Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

A ZEN003694 (ZEN-3694) rákellenes szerek (ZEN-3694) és a talazoparib kombinációjának tesztelése előrehaladott szilárd daganatos betegeknél, a ComBET-próba

2026. november 11. frissítette: National Cancer Institute (NCI)

A BET-inhibitor, a ZEN003694 (ZEN-3694) és a PARP-gátló, a talazoparib kombinációjának 2. fázisú vizsgálata molekulárisan szelektált szilárd daganatos (ComBET) betegeknél

This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Another aim of this study is to find out if, and how, patients' genes influence their response to this specific drug combination. For this part of the study, investigators will run tests using samples of patients' tumor tissue and blood that will be collected during the study. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Genes are pieces of the DNA code that individuals inherit from their parents. Some genes work to protect against cancer by correcting damage that can occur in the DNA when cells divide. BRCA1 and BRCA2 are two examples of these types of genes, and they are called tumor-suppressor genes. For example, if a person has a mutation in a BRCA1/2 gene they have a greatly increased risk of developing breast and ovarian cancer because their cells may no longer be able to completely repair damaged DNA. It is the accumulation of DNA damage which causes a cell to change into a cancerous cell. Other genes are also involved in this process, and these are called DNA damage repair genes. The KRAS mutation is a change in a protein in normal cells. Normally KRAS serves as an information hub for signals in the cell that lead to cell growth, but when there is a mutation in KRAS it signals too much and cells grow without being told to, which causes cancer. Combination therapy with ZEN-3694 and talazoparib may be effective at slowing or stopping tumor growth in patients with advanced cancer.

A tanulmány áttekintése

Részletes leírás

PRIMARY OBJECTIVE:

I. To evaluate clinical response to the combination of BET bromodomain inhibitor ZEN-3694 (ZEN003694 [ZEN-3694]) and talazoparib using objective response rate (ORR) = (complete response [CR] + partial response [PR]).

SECONDARY OBJECTIVES:

I. To confirm the safety and toxicity profile of the combination of ZEN003694 (ZEN-3694) and talazoparib.

II. To evaluate the clinical benefit rate (stable disease [SD] > 6 months [m]+CR+PR) and progression-free survival (PFS).

III. To assess the pharmacodynamics of the combination of ZEN003694 (ZEN-3694) and talazoparib using pre- and on-treatment tumor biopsies.

IV. To characterize pharmacodynamic changes of exploratory biomarkers to the combination of ZEN003694 (ZEN-3694) and talazoparib in pre- and on-treatment tumor biopsies.

V. To assess putative predictive biomarkers of response and resistance to the combination of ZEN003694 (ZEN-3694) and talazoparib.

OUTLINE:

Patients receive ZEN-3694 orally (PO) once daily (QD) and talazoparib PO QD on days 1-28 of each cycle or days 1-5, 8-12, 15-19, and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo diagnostic imaging, blood sample collection, and tumor biopsy throughout the study.

After completion of study treatment, patients are followed up 30 days after administration of the last dose of study drug and then every 3 months for up to 2 years.

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

88

Fázis

  • 2. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

    • California
      • Duarte, California, Egyesült Államok, 91010
        • City of Hope Comprehensive Cancer Center
      • Irvine, California, Egyesült Államok, 92618
        • City of Hope at Irvine Lennar
      • La Jolla, California, Egyesült Államok, 92093
        • UC San Diego Moores Cancer Center
      • Los Angeles, California, Egyesült Államok, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, Egyesült Államok, 90020
        • Keck Medicine of USC Koreatown
      • Los Angeles, California, Egyesült Államok, 90033
        • Los Angeles General Medical Center
      • Newport Beach, California, Egyesült Államok, 92663
        • USC Norris Oncology/Hematology-Newport Beach
      • Sacramento, California, Egyesült Államok, 95817
        • University of California Davis Comprehensive Cancer Center
      • San Diego, California, Egyesült Államok, 92103
        • UC San Diego Medical Center - Hillcrest
    • Colorado
      • Aurora, Colorado, Egyesült Államok, 80045
        • UCHealth University of Colorado Hospital
    • Connecticut
      • New Haven, Connecticut, Egyesült Államok, 06520
        • Yale University
      • Trumbull, Connecticut, Egyesült Államok, 06611
        • Smilow Cancer Hospital Care Center-Trumbull
    • Florida
      • Gainesville, Florida, Egyesült Államok, 32610
        • UF Health Cancer Institute - Gainesville
    • Georgia
      • Atlanta, Georgia, Egyesült Államok, 30322
        • Emory University Hospital/Winship Cancer Institute
    • Illinois
      • Chicago, Illinois, Egyesült Államok, 60611
        • Northwestern University
    • Kansas
      • Fairway, Kansas, Egyesült Államok, 66205
        • University of Kansas Clinical Research Center
      • Kansas City, Kansas, Egyesült Államok, 66160
        • University of Kansas Cancer Center
      • Overland Park, Kansas, Egyesült Államok, 66210
        • University of Kansas Cancer Center-Overland Park
      • Overland Park, Kansas, Egyesült Államok, 66211
        • University of Kansas Hospital-Indian Creek Campus
      • Westwood, Kansas, Egyesült Államok, 66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Kentucky
      • Lexington, Kentucky, Egyesült Államok, 40536
        • University of Kentucky/Markey Cancer Center
    • Louisiana
      • New Orleans, Louisiana, Egyesült Államok, 70121
        • Ochsner Medical Center Jefferson
    • Maryland
      • Bethesda, Maryland, Egyesült Államok, 20892
        • National Institutes of Health Clinical Center
      • Bethesda, Maryland, Egyesült Államok, 20892
        • National Cancer Institute Developmental Therapeutics Clinic
    • Missouri
      • Kansas City, Missouri, Egyesült Államok, 64154
        • University of Kansas Cancer Center - North
      • Lee's Summit, Missouri, Egyesült Államok, 64064
        • University of Kansas Cancer Center - Lee's Summit
      • North Kansas City, Missouri, Egyesült Államok, 64116
        • University of Kansas Cancer Center at North Kansas City Hospital
    • North Carolina
      • Chapel Hill, North Carolina, Egyesült Államok, 27599
        • UNC Lineberger Comprehensive Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Egyesült Államok, 15232
        • UPMC Hillman Cancer Center
    • Texas
      • Austin, Texas, Egyesült Államok, 78712
        • University of Texas at Austin
      • Galveston, Texas, Egyesült Államok, 77555-0565
        • University of Texas Medical Branch
      • Houston, Texas, Egyesült Államok, 77030
        • UT MD Anderson Cancer Center
    • Utah
      • Salt Lake City, Utah, Egyesült Államok, 84112
        • Huntsman Cancer Institute/University of Utah
    • Virginia
      • Charlottesville, Virginia, Egyesült Államok, 22908
        • University of Virginia Cancer Center
      • Richmond, Virginia, Egyesült Államok, 23298
        • VCU Massey Comprehensive Cancer Center

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év és régebbi (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  • Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective

  • Patients must have a tumor lesion that can be biopsied with 'low' or 'minimal' risk and at least one measurable disease site, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1

    • Note: Tumor lesions that are situated in a previously irradiated area may or may not be considered measurable
  • Patients in cohorts 1, 2, and 4 should have at least one relevant mutation. Patients enrolled in cohorts 1-3 do not require that PARP inhibitor (i) be the immediate prior therapy to be eligible for the trial. Patients should sign a screening consent that will allow the review of local next generation sequencing (NGS) or equivalent Clinical Laboratory Improvement Amendment (CLIA)-certified assay results by MD Anderson's Precision Oncology Decision Support (PODS) team to ensure that the mutations are actionable. No variants of uncertain significance (VUS) will be allowed

    • Patients in Cohort 1 must have (i) a germline or somatic mutation in BRCA1 or BRCA2; and (ii) must have received prior PARPi monotherapy or PARPi combination-therapy
    • Patients in Cohort 2 must have: (i) a germline or somatic mutation in any of the following deoxyribonucleic acid (DNA) damage response (DDR) genes: BARD1; FANCA; BRIP1; PALB2; RAD51; RAD51C; RAD51D, with no evidence of mutations in BRCA1 or BRCA2; and (ii) must have received prior PARPi monotherapy or PARPi combination therapy
    • Patients in Cohort 3 must be (i) patients who have had PR/CR on prior PARPi monotherapy or PARPi combination treatment; and (ii) patients with no evidence of BRCA1 or BRCA2 mutations or any of the relevant DDR aberrations listed in cohort 2. Patients with ovarian cancer should not have progressed on platinum-therapy within six months of therapy
    • Patients in Cohort 4 must have KRAS mutated advanced solid tumors. Prior treatments with KRAS inhibitors are permitted. Patients with KRAS G12C mutations must have already had KRAS G12C targeted therapy (e.g., sotorasib) previously
  • Patients must have received at least one line of systemic therapy in the advanced/metastatic setting. Subjects with diseases without known effective options, and subjects who have declined standard of care therapy prior to study introduction, are also eligible. Patients with ovarian cancer in cohort 3 should not have progressed on platinum within six months of therapy

  • Age >= 18 years

    • Because no dosing or adverse event data are currently available on the use of ZEN003694 (ZEN-3694) in combination with talazoparib in patients < 18 years of age, children are excluded from this study
  • Patients must be greater than 4 weeks (6 weeks for nitrosoureas or mitomycin C) beyond treatment with any chemotherapy or other investigational therapy including hormonal, biological, or targeted agents; or at least 5 half-lives from hormonal, biological, or targeted agents, whichever is shorter at the time of treatment initiation. Patients must have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities =< grade 1) with the exception of alopecia or anorexia

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Absolute neutrophil count >= 1,500/mcL

  • Platelets >= 150,000/mcL

  • Hemoglobin >= 10.0 g/dL (no blood transfusions in the preceding 28 days)

  • Total bilirubin 1.5 x =< institutional upper limit of normal (ULN) OR direct bilirubin = ULN for subjects with total bilirubin levels > 1.5 x ULN

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN

  • Creatinine 1.5 x =< institutional ULN OR glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 for subjects with creatinine levels > 1.5 x institutional ULN, unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable viral load while on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment, have discontinued corticosteroid treatment for these metastases for at least 2 weeks, and are neurologically stable. Patients with known symptomatic brain metastases requiring steroids are excluded. Of note, patients who required a single dose of corticosteroids on days receiving radiation treatment do not require a 2-week washout. Follow-up brain imaging after central nervous system (CNS)-directed therapy must show no evidence of progression and patient should be clinically stable for at least 1 month. This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. However, patients with concurrent malignancy that is progressing or requiring active treatment are excluded

  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be of class 2B or better

  • The effects of the combination ZEN003694 (ZEN-3694) and talazoparib on the developing human fetus are unknown. For this reason, and because BET inhibitor agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 months after. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

  • Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 7 months after completion of study drug administration

  • Women of child-bearing potential MUST have a negative serum or urine human chorionic gonadotropin (HCG) test unless prior tubal ligation (>/= 1 year before screening), total hysterectomy, or menopause (defined as 12 consecutive months of amenorrhea)

  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who are receiving any other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 (ZEN-3694) or talazoparib
  • Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 or P-gp, strong inhibitors of BCRP, sensitive substrates of CYP1A2, proton-pump-inhibitors (H2 antagonists are allowed), and herbal medications/preparations (vitamins are allowed) are ineligible. Strong inhibitors or inducers of CYP3A4 must be discontinued at least 7 days prior to the first dose of ZEN003694 (ZEN-3694). Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.
  • Patients with uncontrolled intercurrent illness
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because ZEN003694 (ZEN-3694) is a BET inhibiting agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ZEN003694 (ZEN-3694), breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 1 month following the last dose of the study drug. These potential risks may also apply to other agents used in this study
  • Patients who are involved in the planning and/or conduct of the study
  • Patients who are unable or unwilling to swallow pills
  • Active infection requiring intravenous (IV) antibiotics, or other uncontrolled intercurrent illness requiring hospitalization
  • Patients receiving any medications or substances that are factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed
  • Patients with radiation to > 25% of the bone marrow
  • Patients who have had a bone-targeted radionuclide within 6 weeks of the first dose of ZEN003694 (ZEN-3694) or talazoparib
  • Patients who have previously received ZEN003694 (ZEN-3694) or who have been treated with an investigational BET inhibitor
  • Patients with cerebrovascular accident (CVA), myocardial infarction, or unstable angina within 6 months prior to the first dose of ZEN003694 (ZEN-3694) or talazoparib
  • Patients with impairment of gastrointestinal function that may significantly alter the absorption of ZEN003694 (ZEN-3694) or talazoparib
  • Patients that have had major surgery other than diagnostic surgery, dental surgery, or stenting within 4 weeks prior to the first dose of ZEN003694 (ZEN-3694) or talazoparib

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: N/A
  • Beavatkozó modell: Egyetlen csoportos hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Treatment (ZEN-3694, talazoparib)

Patients receive ZEN-3694 PO QD and talazoparib PO QD on days 1-28 of each cycle or days 1-5, 8-12, 15-19, and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo diagnostic imaging, blood sample collection, and tumor biopsy throughout the study.

Undergo blood sample collection

Más nevek:
  • Biológiai mintagyűjtés
  • Biominta összegyűjtve
  • Mintagyűjtemény
  • Mintagyűjtés

Undergo tumor biopsy

Más nevek:
  • Bx
  • BIOPSY_TYPE
  • Biopszia

Given PO

Más nevek:
  • BETi ZEN-3694
  • ZEN 3694
  • ZEN-3694
  • ZEN003694

Undergo diagnostic imaging

Más nevek:
  • Orvosi képalkotás
  • Diagnosztikai képalkotás

Given PO

Más nevek:
  • 673 BMN
  • BMN-673
  • BMN673

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Objective response rate (ORR)
Időkeret: From initiation of treatment to first response

Systemically assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. ORR = complete response + partial response. Complete response is defined as the disappearance of all target or non-target lesions. Partial response is defined as at least a 30% decrease in the sum of the diameters of target or non-target lesions.

From initiation of treatment to first response

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Duration of response
Időkeret: Time from documentation of tumor response to disease progression, assessed up to 2 years

Assessed using RECIST v1.1.

Time from documentation of tumor response to disease progression, assessed up to 2 years
Clinical benefit rate (CBR)
Időkeret: Up to 2 years

Assessed by radiographic disease assessments per RECIST v1.1. CBR = overall response + stable disease > 6 months. Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

Up to 2 years
Progression-free survival
Időkeret: From start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years

Assessed by radiographic disease assessments per RECIST v1.1.

From start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years
Overall survival
Időkeret: Up to 2 years

Assessed by radiographic disease assessments per RECIST v1.1.

Up to 2 years
Incidence of adverse events
Időkeret: Up to 2 years

Incidence and severity of adverse events and serious adverse events as graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Includes significant changes in laboratory parameters, electrocardiograms, and vital signs. Summarized by grade and type.

Up to 2 years

Egyéb eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Treatment-induced changes in phospho-protein signaling
Időkeret: Up to 2 years

Reverse phase proteomic array in pre- and on-treatment tumor biopsy samples conducted to assess treatment-induced changes in phospho-protein signaling, to correlate with treatment response and progression, and to assess changes in the levels of cytotoxic T lymphocyte precursor.

Up to 2 years
Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response
Időkeret: Up to 2 years

Whole exome sequencing conducted on pre-treatment biopsy and at progression to correlate SNV and CNV profiles with treatment response.

Up to 2 years
Gene expression profiling
Időkeret: At pre-treatment, on-treatment, and at progression

Ribonucleic acid (RNA) sequencing conducted for gene expression profiling.

At pre-treatment, on-treatment, and at progression
Correlate mutation profiles with tumor sequencing
Időkeret: Up to 2 years

Using circulating tumor deoxyribonucleic acid (ctDNA) for correlation.

Up to 2 years
Correlate baseline mutations with treatment response
Időkeret: Up to 2 years

Using ctDNA for correlation.

Up to 2 years
Correlate changes in ctDNA variant allele frequencies with response
Időkeret: Up to 2 years

Using ctDNA for correlation.

Up to 2 years
Assess emergent resistant mutations
Időkeret: At progression

Includes BRCA reversion.

At progression
Analysis of formalin-fixed paraffin-embedded and blood and blood samples
Időkeret: Up to 2 years

DNA, RNA, and protein analysis conducted.

Up to 2 years

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Nyomozók

  • Kutatásvezető: Timothy A Yap, University of Texas MD Anderson Cancer Center LAO

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2022. november 14.

Elsődleges befejezés (Becsült)

2026. december 31.

A tanulmány befejezése (Becsült)

2026. december 31.

Tanulmányi regisztráció dátumai

Először benyújtva

2022. április 13.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2022. április 13.

Első közzététel (Tényleges)

2022. április 14.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 12.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 11.

Utolsó ellenőrzés

2026. szeptember 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Egyéb vizsgálati azonosító számok

  • NCI-2022-02915
  • UM1CA186688 (Az Egyesült Államok NIH támogatása/szerződése)
  • NCI-2022-02915 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • 10486 (Egyéb azonosító: CTEP)
  • NCI10486
  • 10486 (Egyéb azonosító: University of Texas MD Anderson Cancer Center LAO)

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

IGEN

IPD terv leírása

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Igen

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel